Press Releases :: Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Mar 7, 2022

Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

Feb 7, 2022

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Dec 6, 2021

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

Nov 12, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

Nov 8, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

Nov 1, 2021

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update

Oct 27, 2021

Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek

Oct 4, 2021

Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

Sep 29, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference

Sep 27, 2021